Specifically, the chemokine IL8 has been shown to underpin the angiogenic response of HIF-1α–deficient/VEGF-depleted DLD-1 colon cancer xenografts (31), and mediate the resistance of head and neck squamous cell carcinoma and renal cell carcinoma to Bevacizumab (32) and Sunitinib (33), respectively. Here, CXCL8 is linked to hereditary clear cell renal cell carcinoma.